

IPCR - Contributions for ISAA report no. 78 on COVID-19 - Answers

Questionnaire published on 22/09/2021 16:02 CET

1. PUBLIC HEALTH AND TESTING

1.1. Public health and testing strategy

1.1.1. What testing strategy is currently in place in your country? Please specify the approach used with regards to both symptomatic and asymptomatic testing. Please indicate your approach to testing of close contacts, if relevant, and whether you carry out testing for epidemiological surveillance.

Netherlands	We test all symptomatic persons. Since the first of december, asymptomatic persons that have been identified as close contacts and close contacts that are being found through CoronaMelder (a contact tracing app) can get tested on the first and 5th day of quarantine. In case the test is negative, quarantine can be ended. Since january 20th all incoming travellers can get tested on the 5th day of quarantine. In case the test is negative, quarantine can be ended. We also test asymptomatic people in outbreak clusters such as in hospices of abbatoirs. Since the 19th of April all teachers in primary and secondary education get use a self-test (antigen) twice a week for preventive testing. Since the beginning of april we've started testing for access.	27/09/2021 07:58 CET
-------------	--	----------------------

1.1.2. Are you currently using rapid antigen tests?

Netherlands	YES. YES, these results are accepted as a basis for public health measures (e.g. lifting	27/09/2021 07:58 CET
-------------	---	----------------------

Questionnaire published on 22/09/2021 16:02 CETLIMITE1

	of quarantine obligations or mask wearing, allowing entry into public spaces, etc.).	
<p>Summary for all Core User Groups:</p> <p>YES.: 14</p> <p>NO.: 0</p> <p>YES, these results are accepted as a basis for public health measures (e.g. lifting of quarantine obligations or mask wearing, allowing entry into public spaces, etc.): 7</p> <p>YES, these results are accepted in the context of travel – there is mandatory/voluntary rapid antigen testing available upon arrival at the airport.: 7</p> <p>YES, these results are accepted in the context of travel – arriving travellers are allowed to carry a negative COVID-19 test result based on a rapid antigen test.: 7</p> <p>If YES, and you wish to further specify.: 7</p>		

1.1.3. Are you currently using rapid antigen self-tests? If yes, please specify in which context and for what purpose (e.g. testing at schools, at companies, in health care facilities, etc.).

Netherlands	<p>YES.</p> <p>If YES, please specify: - Yes, e.g. testing at schools, testing for incoming travellers as safety measure</p>	27/09/2021 07:58 CET
<p>Summary for all Core User Groups:</p> <p>YES.: 12</p> <p>NO.: 2</p> <p>If YES, please specify: : 12</p>		

1.1.4. Are you currently using antibody tests? If yes, please specify their current purpose (e.g. for seroprevalence studies, for implementation of specific public health measures, etc).

Netherlands	YES. If YES, please specify: - Antibody tests are used as recovery evidence. When antibodies are detected, 1 vaccination will fulfill.	27/09/2021 07:58 CET
Summary for all Core User Groups: YES.: 11 NO.: 4 If YES, please specify.: 10		

1.1.5. How many SARS-CoV-2 positive samples do you sequence, on average, per week?

Netherlands	More than 10% / more than 500 samples.	27/09/2021 07:58 CET
Summary for all Core User Groups: More than 10% / more than 500 samples.: 10 Between 5-10% / between 250-500 samples.: 4 Between 1-5% / between 50-250 samples.: 1 Less than 1% / less than 50 samples.: 0 No data reported.: 0		

1.1.6. Has your country identified any particular issues with regards to sequencing capacity? Or shortages in laboratory staff?

Netherlands	NO.	27/09/2021 07:58 CET
Summary for all Core User Groups:		

YES.: 4 NO.: 7 If YES, please specify what issues have been identified and what measures have been implemented to address these gaps: : 6

1.2. Passenger locator forms

1.2.1. Do you intend to connect the digital passenger locator form (PLF) for one or more transport modes to the ePLF platform? If so, for which means of transport?

Netherlands	NO, please specify the reasons: - The Netherlands does not make use of the digital passenger locator form	27/09/2021 07:58 CET
Summary for all Core User Groups: YES, airplane PLF.: 8 YES, train PLF.: 3 YES, bus PLF.: 3 YES, cruise ships PLF.: 5 YES, ferries PLF.: 3 NO, please specify the reasons: : 4		

1.2.2. How many crossborder contact tracing are performed per week?

Netherlands	Less than 50.	27/09/2021 07:58 CET
Summary for all Core User Groups: Less than 50.: 5 50-100.: 0		

100-500.: 3
500-1000.: 0
1000-5000.: 0
More than 5000 per month.: 0

1.2.3. How many messages containing PLF data are exchanged with other Member States through the ePLF(*) exchange platform every month? (*please note, not through the EWRS selective exchange platform)

Summary for all Core User Groups:
Less than 50.: 2
50-100.: 0
100-500.: 2
500-1000.: 0
1000-5000.: 0
More than 5000 per month.: 1

1.3. Case management

1.3.1. How many Intensive Care Units (ICU) for COVID-19 patients are available in your country? (only insert the number – no text)

Netherlands	200	27/09/2021 07:58 CET
Total for all Core User Groups: 15264		

1.3.2. What % of Intensive Care Units (ICU) are currently occupied with COVID-19 patients? (only insert the number (%)) – no text)

Netherlands	91.5	27/09/2021 07:58 CET
-------------	------	----------------------

Total for all Core User Groups: 365.1

1.3.3. How many additional Intensive care beds can you set up as surge capacity? (only insert the number – no text)

Total for all Core User Groups: 15425

2. COVID-19 CERTIFICATES

2.1. COVID-19 certificates

2.1.1. How are you using vaccination certificates?

Netherlands	YES, for travel use. YES, for access to specific places/events (e.g. restaurants, museums, concerts, etc.).	27/09/2021 07:58 CET
<p>Summary for all Core User Groups:</p> <p>YES, for medical use only.: 2</p> <p>YES, for travel use.: 15</p> <p>YES, for access to specific places/events (e.g. restaurants, museums, concerts, etc.): 11</p> <p>NO.: 0</p> <p>Under discussion.: 1</p> <p>Other, please specify : 6</p>		

3. COVID-19 VACCINATION STRATEGIES

3.1. COVID-19 vaccination strategies

Questionnaire published on 22/09/2021 16:02 CETLIMITE6

3.1.1. Is your country recommending COVID-19 vaccination for pregnant women?

Netherlands	YES, but only certain vaccine products are recommended.	27/09/2021 07:58 CET
Summary for all Core User Groups:		
YES, any of the vaccine products are recommended.: 5		
YES, but only certain vaccine products are recommended.: 10		
NO, we do not recommend that pregnant women get vaccinated.: 0		
If YES, please specify which vaccine products and timing (e.g. during third trimester): : 9		

3.1.2. Has your country made the decision to recommend an additional vaccine dose to subjects who may experience a limited response to the primary series of COVID-19 vaccination (e.g. extended primary series) or to recommend a 'booster dose' to vaccinated people due to possible waned immunity and protection?

Netherlands	YES, but only an additional dose to individuals with a weakened immune system (e.g. extended primary series).	27/09/2021 07:58 CET
Summary for all Core User Groups:		
YES, but only an additional dose to individuals with a weakened immune system (e.g. extended primary series):. 6		
YES, both an additional dose to individuals with a weakened immune system (e.g. extended primary series) AND a 'booster' dose to vaccinated people.: 8		
NO.: 0		
Under discussion.: 1		
Other, please specify.: 2		

3.1.3. If your country has made a recommendation for an additional dose or a booster dose, can you please provide the link to the official recommendation?

Netherlands	https://www.gezondheidsraad.nl/documenten/adviezen/2021/09/14/boostervaccinatie-tegen-covid-19 https://www.rivm.nl/covid-19-vaccinatie/vragen-achtergronden/immuungecompromitteerden (defining specific groups of immunocompromised patients for a third dose)	27/09/2021 07:58 CET
-------------	---	-------------------------

3.1.4. If your country has made the decision to recommend an additional dose of a booster dose, have you started administering them already?

Netherlands	NO, but we plan in the future (please specify when in the text box.	27/09/2021 07:58 CET
Summary for all Core User Groups:		
YES, we have started administering doses already (please specify the date you started in the text box): 10		
NO, but we plan in the future (please specify when in the text box): 3		
Please provide details: : 9		

3.1.5. If your country is recommending an additional dose or a booster dose, for which population groups are they currently indicated?

Netherlands	Immunocompromised/immunosuppressed individuals.	27/09/2021 07:58 CET
Summary for all Core User Groups:		
Immunocompromised/immunosuppressed individuals.: 21		
Immunocompromised/immunosuppressed individuals.: 21		
LTCF residents.: 7		
Healthcare workers.: 4		
The general population.: 2		
Other population groups (please specify the group/s): 3		

Please provide details: : 7

3.1.6. If your country is recommending an additional dose or a booster dose, will it or is it administered using:

Netherlands	A heterologous ('mix and match') regimen (please specify the recommended schedule).	27/09/2021 07:58 CET
Summary for all Core User Groups: A homologous (same vaccine product as primary vaccination course) regimen.: 9 A heterologous ('mix and match') regimen (please specify the recommended schedule).: 7 Please provide details: : 10		

3.1.7. If your country is recommending an additional dose or a booster dose, which time interval after the primary vaccination schedule do you recommend (including different time intervals depending on population groups)? Please provide details.

Netherlands	At least 4 weeks after the primary vaccination schedule.	27/09/2021 07:58 CET
-------------	--	----------------------

3.1.8. If your country is recommending a booster dose, will the COVID-19 booster dose be incorporated in the yearly seasonal influenza vaccination campaign?

Netherlands	Under discussion. - No decision have been made yet.	27/09/2021 07:58 CET
Summary for all Core User Groups: YES.: 1 NO.: 4 Under discussion.: 7		

3.1.9. If your country is planning to incorporate the administration of the booster dose with the yearly seasonal influenza vaccination campaign, what is the planned interval spacing between the COVID-19 vaccine dose and the flu vaccine dose?

Netherlands	Two weeks.	27/09/2021 07:58 CET
Summary for all Core User Groups: No spacing, both vaccines will be administered at the same time.: 1 Two weeks.: 3 Other, please specify: : 4		

3.1.10. Is your country administering a heterologous combination of vaccine doses ('mix and match') (e.g. Vaxzevria first dose followed by Comirnaty for second dose)?

Netherlands	YES (please specify below).	27/09/2021 07:58 CET
Summary for all Core User Groups: YES (please specify below): 11 NO.: 4 Under discussion.: 0 If YES, please provide details on which combinations of vaccines are part of this schedule and what is the reason for using heterologous vaccination schedules in your country: : 11		

3.1.11. Does your country recommend the use of specific vaccine products for particular age groups and/or target groups? (E.g. Vaxzevria or Janssen for different age groups).

Netherlands	YES, some vaccines are restricted to specific age groups and/or individuals with specific contraindications (please specify).	27/09/2021 07:58 CET
Summary for all Core User Groups:		

YES, some vaccines are restricted to specific age groups and/or individuals with specific contraindications (please specify): 9
NO, we follow the EMA summary of product characteristics (SmPC) for all vaccines.: 4
Currently under discussion.: 0
If YES, please explain in more detail the recommendations for different vaccine products for different age categories or target groups: : 9

3.1.12. What is the recommendation for vaccinating those individuals who have been previously infected with SARS-CoV-2?

Netherlands	YES, with one dose (for vaccines that have a two-dose regimen).	27/09/2021 07:58 CET
Summary for all Core User Groups:		
YES, with the full vaccination course.: 10		
YES, with one dose (for vaccines that have a two-dose regimen).: 8		
NO vaccination is recommended in previously infected individuals.: 0		
Currently under discussion.: 1		

3.1.13. If your country is only offering one dose of vaccination to those previously infected, after how long since a person has been infected do you recommend vaccination (for example, vaccination is recommended in individuals previously infected with SARS-CoV-2 three to six months after recovery)

Netherlands	<3 months after infection.	27/09/2021 07:58 CET
Summary for all Core User Groups:		
<3 months after infection.: 2		
3 months after infection.: 1		
6 months after infection.: 2		
8 months after infection.: 0		
Other, please specify: : 6		

3.1.14. If your country is only offering one dose or is not recommending vaccination to those previously infected how are you verifying documentation of previous infection? (E.g. proof of a laboratory test which confirms infection, integrated health information systems.) *

Netherlands	No proof is required, self-declaration is sufficient.	27/09/2021 07:58 CET
Summary for all Core User Groups:		
Proof of infection through a laboratory test certificate.: 2		
Proof of infection based on a laboratory test accessed through integrated health system.: 6		
No proof is required, self-declaration is sufficient.: 1		
Other, please specify: : 0		

3.1.15. Has there been any change in the vaccination strategy in light of the circulation of new variants of concern?

Netherlands	NO.	27/09/2021 07:58 CET
Summary for all Core User Groups:		
Reducing the timing between first and second dose.: 6		
Adaption of priority groups.: 0		
Use of one-dose vaccine product for certain target groups.: 0		
Prioritisation of vaccines to geographical areas where new variants have been circulating (e.g. surge vaccination).: 0		
NO.: 8		
Other, please specify in more detail the changes in the vaccination strategy: : 5		

3.1.16. Is your country vaccinating adolescents aged 12-17 years?

Netherlands	YES, all adolescents.	27/09/2021 07:58 CET
-------------	-----------------------	----------------------

<p>Summary for all Core User Groups:</p> <p>YES, all adolescents.: 15</p> <p>YES, but only adolescents with risk factors.: 0</p> <p>NO.: 0</p> <p>Under discussion.: 0</p>
--

3.1.17. For adolescents, is the authorized EMA indication / use of COVID-19 vaccines followed or do you have national recommendations?

Netherlands	We follow EMA authorised indication.	27/09/2021 07:58 CET
<p>Summary for all Core User Groups:</p> <p>We follow EMA authorised indication.: 12</p> <p>We have national recommendations.: 2</p> <p>If you have national recommendations, please explain what these recommendations are: : 3</p>		

3.1.18. If adolescent vaccination is recommended at national level, what is the timing?

Netherlands	It has started.	27/09/2021 07:58 CET
<p>Summary for all Core User Groups:</p> <p>It has started.: 15</p> <p>It will start in the autumn.: 0</p> <p>It will take place with the start of the new school year.: 0</p> <p>Under discussion.: 0</p>		

3.1.19. If adolescent vaccination is recommended at national level, where is it taking/will take place?

Netherlands	Vaccination centres.	27/09/2021 07:58 CET
Summary for all Core User Groups: Vaccination centres.: 13 Schools.: 4 Peadeatricain clinics.: 1 Family doctors.: 3 Hospitals.: 2 Other, please specify: : 4		

3.1.20. Is vaccination mandatory in your country?

Netherlands	NO.	27/09/2021 07:58 CET
Summary for all Core User Groups: YES, for everyone.: 0 YES, but only for certain population groups (please specify below).: 0 NO.: 16 Tex box for specifications: : 0		

3.2. COVID-19 vaccination roll-out

3.2.1. Do you observe any vaccine hesitancy in any specific population or age group and for any specific vaccines in particular?

Netherlands	YES. Please provide details about population or age groups or hesitancy for specific vaccines in particular and any available reference or details of the source for this information: - .	27/09/2021 07:58 CET
-------------	--	----------------------

<p>Summary for all Core User Groups:</p> <p>YES. Please provide details about population or age groups or hesitancy for specific vaccines in particular and any available reference or details of the source for this information: : 10</p> <p>NO.: 3</p>

3.2.2. In regards to vaccine hesitancy, what percentage of the population, on average, have not yet been vaccinated but are willing to get vaccinated?

Netherlands	<p><10%.</p> <p>Please provide any available reference or details of the source for this information: Research of the RIVM shows that ~1,3% is willing or has made an appointment for covid-19-vaccination. https://www.rivm.nl/gedragsonderzoek/trendonderzoek</p>	27/09/2021 07:58 CET
<p>Summary for all Core User Groups:</p> <p><10%.: 4</p> <p>10-30%.: 2</p> <p>31-60%.: 0</p> <p>>60%.: 0</p> <p>No information.: 6</p> <p>Please provide any available reference or details of the source for this information: : 2</p>		

3.2.3. In regards to vaccine hesitancy, what percentage of the population, have not yet been vaccinated and are uncertain if they will get vaccinated?

Netherlands	<p><10%.</p> <p>Please provide any available reference or details of the source for this information:</p>	27/09/2021 07:58 CET
-------------	--	----------------------

	91% willingness uptake first vaccination (this percentage includes both the people that have taken a vaccination or that are willing to take vaccination). 9% not yet and part of this will be hesistance. This percentage is probably an underestimate, due to sample.	
<p>Summary for all Core User Groups:</p> <p><10%.: 3</p> <p>10-30%.: 4</p> <p>31-60%.: 0</p> <p>>60%.: 0</p> <p>No information.: 6</p> <p>Please provide any available reference or details of the source for this information: : 2</p>		

3.2.4. In regards to vaccine hesitancy, what percentage of the population, on average, have not yet been vaccinated and are not willing to get vaccinated?

Netherlands	<p><10%.</p> <p>Please provide any available reference or details of the source for this information:</p> <p>91% willingness uptake first vaccination (this percentage includes both the people that have taken a vaccination or that are willing to take vaccination). 9% not yet and part of this will be hesistance. This percentage is probably an underestimate, due to sample.</p>	27/09/2021 07:58 CET
<p>Summary for all Core User Groups:</p> <p><10%.: 4</p> <p>10-30%.: 3</p>		

31-60%.: 1
>60%.: 0
No information.: 5
Please provide any available reference or details of the source for this information: : 3

3.2.5. Is your country facing challenges with increasing uptake in the priority groups of healthcare workers and/or long-term care facilities workers?

Netherlands	NO.	27/09/2021 07:58 CET
Summary for all Core User Groups:		
YES. Please provide further details about these challenges and any solutions or measures you have put in place to mitigate these challenges: : 5		
NO.: 8		

3.2.6. Is your country facing challenges to increase the uptake in the elderly population?

Netherlands	YES. Please provide further details about these challenges and any solutions or measures you have put in place to mitigate these challenges: - .	27/09/2021 07:58 CET
Summary for all Core User Groups:		
YES. Please provide further details about these challenges and any solutions or measures you have put in place to mitigate these challenges: : 4		
NO.: 9		

3.2.7. Is your country facing challenges with increasing uptake in young adults and adolescents (approx. 12-35 years)?

Netherlands	YES. Please provide further details about these challenges and any solutions or measures you have put in place to mitigate these challenges: - .	27/09/2021 07:58 CET
<p>Summary for all Core User Groups:</p> <p>YES. Please provide further details about these challenges and any solutions or measures you have put in place to mitigate these challenges: : 7</p> <p>NO.: 6</p>		

3.2.8. Is your country facing challenges with increasing uptake or access to vaccination for any of the following socially vulnerable or underserved populations?

Netherlands	<p>Ethnic minorities.</p> <p>Low socio-economic strata.</p> <p>Particular groups that are identified as specifically resistant to vaccination identified through national surveys (please specify below).</p> <p>Text box for specifications: - groups with often a more general hesistance against government and governmental institutions</p>	27/09/2021 07:58 CET
<p>Summary for all Core User Groups:</p> <p>Irregular migrants.: 2</p> <p>Ethnic minorities.: 5</p> <p>People experiencing homelessness.: 1</p> <p>People with alcohol or drug dependence.: 1</p> <p>People with mobility issues.: 0</p> <p>People with disabilities (long-term physical, mental, intellectual, or sensory impairments):. 0</p> <p>LGBTI communities.: 0</p>		

Prison populations.: 0
 Low socio-economic strata.: 3
 Particular groups that are identified as specifically resistant to vaccination identified through national surveys (please specify below): 2
 Other, please specify below.: 2
 Text box for specifications: : 6

3.2.9. What strategies and measures do you have in place or plan to put in place for reaching underserved/socially vulnerable populations for vaccination?

Netherlands	Community participation in service delivery. Intersectoral partnerships for community-based interventions. Outreach initiatives. Mobile and pop up vaccination teams/clinics. Targeted communication strategies. Social media campaigns. Other, please specify: - ocal influencers for specific target groups development and use of specific education materials for use in secondary schools, vocational education and training and higher education	27/09/2021 07:58 CET
Summary for all Core User Groups: Community participation in service delivery.: 6 Intersectoral partnerships for community-based interventions.: 7 Outreach initiatives.: 8 Mobile and pop up vaccination teams/clinics.: 9 Targeted communication strategies.: 9		

Social media campaigns.: 5 Other, please specify: : 2
--

3.2.10. Is your country facing challenges around communication and uptake of vaccines?

Netherlands	<p>Communicating with different population groups.</p> <p>Communicating adaptations made to vaccination strategies.</p> <p>Communicating about prioritisation of population groups and the rationale behind the choices.</p> <p>Communicating about vaccine safety.</p> <p>Other, please specify below.</p> <p>Text box for specifications: - Communication about the speed of vaccine development, consequences for pregnant women or for fertility, side-effects of vaccines, how mRNA vaccines work.</p>	27/09/2021 07:58 CET
<p>Summary for all Core User Groups:</p> <p>Communicating with different population groups.: 6</p> <p>Communicating adaptations made to vaccination strategies.: 2</p> <p>Communicating about prioritisation of population groups and the rationale behind the choices.: 1</p> <p>Communicating about vaccine safety.: 4</p> <p>Other, please specify below.: 3</p> <p>Text box for specifications: : 5</p>		

3.2.11. Is your country implementing any communication, engagement initiatives and/or offering different incentive schemes to increase vaccination uptake (e.g. vouchers or lottery)?

Netherlands	NO.	27/09/2021 07:58 CET
Summary for all Core User Groups: YES (please specify in the text box below): 7 NO.: 8 Under discussion.: 1 If YES, please provide any details of initiatives being put in place.: 5		

3.3. COVID-19 vaccine roll-out overview

3.3.1. Has your country identified broader impact on health care provision, e.g. in terms of delay in the provision of non-COVID related healthcare services?

Netherlands	YES.	27/09/2021 07:58 CET
Summary for all Core User Groups: YES.: 9 NO.: 3 Please specify: : 4		

3.3.2. What is your country's approach to ensure capacities in other non-COVID related healthcare services?

Netherlands	Framework and agreement about prioritization of care: urgent, semi-urgent and critical planable care (to be provided > 6 weeks) are prioritized. If needed to ensure the access to these types of care, other planable treatments will be postponed.	27/09/2021 07:58 CET
-------------	--	----------------------

3.3.3. Has there been any disruptions of/delays in childhood vaccination programmes?

Summary for all Core User Groups:

YES.: 2

NO.: 7

Under evaluation.: 3

If YES, please specify: : 2

4. COVID-19 therapeutics

4.1. Which therapeutics are in use for COVID-19 patients (either under a compassionate use scheme and/or as part of clinical trials and/or with an emergency use authorization)?

Netherlands	Casirivimab / imdevimab (REGN-CoV2). (Ro)Actemra (Tocilizumab). Other, please specify: - remdesivir, nanogram+.	27/09/2021 07:58 CET
<p>Summary for all Core User Groups:</p> <p>Olumiant (Baricitinib): 3</p> <p>Bamlanivimab / etesevimab.: 1</p> <p>Casirivimab / imdevimab (REGN-CoV2): 3</p> <p>Regdanivimab.: 1</p> <p>Sotrovimab (Xevudy (VIR-7831)): 2</p> <p>Molnupiravir.: 1</p> <p>(Ro)Actemra (Tocilizumab): 6</p> <p>PF-07321332 together with Ritoravir.: 1</p> <p>PF-07304814.: 0</p>		

Kevzara (sarilumab): 0 Lenzilumab: 0 Kineret (anakinra): 2 Other, please specify : 3

4.2. Are you running tendering procedures of any of these medicines (NOT through the EC Joint Procurement Agreement)?

Netherlands	NO.	27/09/2021 07:58 CET
Summary for all Core User Groups: YES.: 1 NO.: 4 Under discussion.: 1		

4.3. How many clinical trials on COVID-19 therapeutics are ongoing in your country?

Netherlands	35	27/09/2021 07:58 CET
-------------	----	----------------------

4.4. How many of these clinical trials are multinational (>3= Member States concerned)?

Netherlands	7	27/09/2021 07:58 CET
-------------	---	----------------------

4.5. Do the clinical trials include pediatric population?

Netherlands	NO.	27/09/2021 07:58 CET
Summary for all Core User Groups:		

YES.: 1 NO.: 6 Under discussion.: 0

4.6. Are the clinical trials open for pregnant or breastfeeding women?

Netherlands	NO.	27/09/2021 07:58 CET
Summary for all Core User Groups: YES.: 0 NO.: 7 Under discussion.: 0		

5. BORDERS AND MOBILITY

5.1. Difficulties with internal and external border restrictions concerning the transport of goods

5.1.1. Has your country experienced difficulties with clearance of goods at external borders (notably medicine, PPE)?

Summary for all Core User Groups: YES.: 0 NO.: 9 Please specify.: 0
--

6. SECTOR-SPECIFIC RESPONSE

6.1. Waterborne transport

Questionnaire published on 22/09/2021 16:02 CETLIMITE24

6.1.1. Is your country already vaccinating seafarers or has plans to do so?

Summary for all Core User Groups:

YES.: 4

NO.: 5

If YES, please specify how many seafarers have already been vaccinated and whether this include only residents: :: 4

6.1.2. Is your country currently restricting entry for seafarers from South Asia (India, Pakistan, Bangladesh, Sri Lanka)?

Summary for all Core User Groups:

YES.: 1

NO.: 8

Please specify:: 3

6.2. Aviation

6.2.1. Do you provide aviation sector access to short time work scheme; salary support scheme; temporary unemployment scheme?

Summary for all Core User Groups:

YES.: 5

NO.: 3

Please specify:: 3

6.2.2. Do you provide loans or loan guarantees to aviation sector?

Summary for all Core User Groups:

YES.: 6 NO.: 4 Please specify.: 2

6.2.3. What other support or aid is available to aviation sector?

6.3. Support to SME

6.3.1. To support SMEs, has your country implemented grants and financial transfers to businesses including wage subsidies?

Summary for all Core User Groups: YES.: 13 NO.: 0 Please specify.: 7

6.4. Socio-economic impact

6.4.1. Are there any activities in place to monitor / model economic / social impacts? How are these included in the exit strategy?

7. EUROPEAN CITIZENS INITIATIVES*

7.1. Questions in relation to European Citizens Initiatives – COVID-19 extension of collection periods of initiatives

7.1.1. Does your country apply COVID-19 containment measures within your country? COVID-19 containment (also referred to as confinement) measures refer here to a set of measures that prohibit citizens from moving around freely

Netherlands	NO.	27/09/2021 07:58 CET
-------------	-----	----------------------

<p>Summary for all Core User Groups:</p> <p>YES.: 2</p> <p>NO.: 8</p> <p>NO, but with exceptions at local/regional level; please provide the approximate percentage of the country's population affected...%.: 2</p> <p>Please provide details.: 3</p>
--

7.1.2. If and to what extent are public spaces (including parks and other recreational spaces, public service institutions, shopping areas and market places) open to the public?

Netherlands	<p>Partially open.</p> <p>Please provide details: - All public spaces are open, some with restrictions on opening times (for example, restaurant/bars closed from 0:00-6:00). Some public spaces are only accessible with a 'CoronaToegangsBewijs' (CTB) (Covid-pass), such as restaurants/bars, theaters, events.</p>	27/09/2021 07:58 CET
<p>Summary for all Core User Groups:</p> <p>Fully open.: 10</p> <p>Partially open.: 4</p> <p>Closed.: 0</p> <p>Please provide details.: 6</p>		

7.1.3. If and to what extent are meetings, public or private gatherings and events allowed? Please indicate the level of capacity restrictions, by indicating the number of maximum people allowed (covering both inside and outside, taking the highest number where applicable).

Netherlands	More than 1 000 persons (or no restrictions).	27/09/2021 07:58 CET
<p>Summary for all Core User Groups:</p>		

More than 1 000 persons (or no restrictions):	4
Between 500 and 1 000 persons:	1
Between 200 and 500 persons:	3
Up to 100 - 200 persons:	0
Not allowed, or only up to 10 - 20 persons:	1
Please provide details:	9